Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

AB-836

Other · developed by Arbutus Biopharma

Phase 1 Most advanced trial (none active)
ABUS Developer
1 Registered trials

What is AB-836?

AB-836 is an investigational drug studied in Chronic Hepatitis.

At a glance

Drug type
Other
Therapy area
Gastroenterology
Developer
Arbutus Biopharma Corporation (ABUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
MHY5H5WMW6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04775797 Phase 1 Chronic Hepatitis Terminated ABUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Hepatitis

More from Arbutus Biopharma

ARB-001467 Phase 2 Imdusiran Phase 2 Peg-IFNα-2a Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-100802 Phase 1 TKM-PLK1 Phase 1/2

Follow ABUS, the company behind AB-836

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.